Monitoring of the End-tidal Carbon Dioxide (EtCO2) as a Severity Criterion in COPD Exacerbations
Recruiting
Observational Study
Pulmonary Disease, Chronic Obstructive
Exacerbation Copd
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 240 (estimated)
- Sponsor
- University Hospital, Grenoble · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Although we know that these numbers are underestimated, Chronic obstructive pulmonary disease (COPD) is a common chronic respiratory disease that affects between 8 and 12% of adults. According to a 2020 WHO report, it is the third most common cause of mortality in developed countries. This disease is punctuated by exacerbations associated with an 8% mortality of hospitalized patients, increased to…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* All patient presenting to the emergency department with acute dyspnea and with a history of COPD documented or reported by the patient and/or family
* Male or female≥18 years old who did not oppose to participating in the study
Exclusion Criteria:
* Hypotension (SBP \< 90 mm…
Contacts